Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17823066 | 0.99 | KMT2A (0.38) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| SCHEMBL17823083 | 0.90 | KDM4E (0.42) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| Hydrochloric Acid SCHEMBL17823071 | 0.89 | KDM4E (0.41) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| SCHEMBL17822993 | 0.88 | CHEK2 (0.43) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| SCHEMBL17823092 | 0.88 | LRRK2 (0.42) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| Hydrochloric Acid SCHEMBL19715278 | 0.87 | CHEK2 (0.42) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| Hydrochloric Acid SCHEMBL17822988 | 0.87 | LRRK2 (0.41) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| SCHEMBL19715268 | 0.82 | MAPK14 (0.41) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| SCHEMBL17832405 | 0.82 | KMT2A (0.40) | ALDH1A1KMT2AKDM4EHPGDGLA | |
| Hydrochloric Acid SCHEMBL19715283 | 0.81 | MAPK14 (0.40) | ALDH1A1KMT2AKDM4EHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207474-B | Substituted heterocycles as bromodomain inhibitors | 恒翼生物医药科技(上海)有限公司 | 2021-05-07 | — | — | CN | claimed |
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | claimed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | claimed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | claimed |
| EP-3230277-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Ltd. (CA) | 2017-10-18 | — | — | EP | claimed |
| WO-2016092375-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-16 | — | — | WO | claimed |
| CN-107207474-B | Substituted heterocycles as bromodomain inhibitors | 恒翼生物医药科技(上海)有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3230277-B1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2019-09-18 | — | — | EP | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-05-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| EP-3230277-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Ltd. (CA) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092375-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360756-A1 | SUBSTITUTED HETEROCYCLES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ALDH1A1 3607/4885KMT2A 727/4885KDM4E 524/4885 |
| US-10292968-B2 | Substituted heterocycles as bromodomain inhibitors | BRD4, BRD3, BRD1 | ALDH1A1 3607/4885KMT2A 727/4885KDM4E 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.